Treatment optimization and genomic outcomes in refractory severe aplastic anemia treated with eltrombopag

Eltrombopag (EPAG) received approval from the US Food and Drug Administration for the treatment of refractory severe aplastic anemia (rSAA) based on treatment of 43 patients with doses escalating from 50 to 150 mg daily for 12 weeks. Response kinetics suggested that more prolonged administration of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Winkler, Thomas, Fan, Xing, Cooper, James, Desmond, Ronan, Young, David J., Townsley, Danielle M., Scheinberg, Phillip, Grasmeder, Sophia, Larochelle, Andre, Desierto, Marie, Valdez, Janet, Lotter, Jennifer, Wu, Colin, Shalhoub, Ruba N., Calvo, Katherine R., Young, Neal S., Dunbar, Cynthia E.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2019
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6566590/
https://ncbi.nlm.nih.gov/pubmed/30992268
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019000478
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados